日本ケミファの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/01/31 | 1,592 | 1,612 | 1,592 | 1,601 | +12 | +0.8% | 5,100 |
| 2024/01/30 | 1,630 | 1,634 | 1,589 | 1,589 | -21 | -1.3% | 28,300 |
| 2024/01/29 | 1,628 | 1,628 | 1,608 | 1,610 | +3 | +0.2% | 2,900 |
| 2024/01/26 | 1,610 | 1,622 | 1,605 | 1,607 | -4 | -0.2% | 5,300 |
| 2024/01/25 | 1,608 | 1,628 | 1,604 | 1,611 | +8 | +0.5% | 7,300 |
| 2024/01/24 | 1,600 | 1,612 | 1,600 | 1,603 | +4 | +0.3% | 4,200 |
| 2024/01/23 | 1,609 | 1,610 | 1,599 | 1,599 | ±0 | ±0% | 6,200 |
| 2024/01/22 | 1,590 | 1,609 | 1,590 | 1,599 | +8 | +0.5% | 5,600 |
| 2024/01/19 | 1,593 | 1,600 | 1,591 | 1,591 | -3 | -0.2% | 2,600 |
| 2024/01/18 | 1,600 | 1,606 | 1,594 | 1,594 | -8 | -0.5% | 6,400 |
| 2024/01/17 | 1,601 | 1,613 | 1,600 | 1,602 | -5 | -0.3% | 5,000 |
| 2024/01/16 | 1,618 | 1,618 | 1,602 | 1,607 | -9 | -0.6% | 4,200 |
| 2024/01/15 | 1,615 | 1,621 | 1,613 | 1,616 | +1 | +0.1% | 5,300 |
| 2024/01/12 | 1,615 | 1,622 | 1,613 | 1,615 | ±0 | ±0% | 3,400 |
| 2024/01/11 | 1,615 | 1,623 | 1,613 | 1,615 | +4 | +0.2% | 4,400 |
| 2024/01/10 | 1,607 | 1,622 | 1,605 | 1,611 | -1 | -0.1% | 3,600 |
| 2024/01/09 | 1,614 | 1,616 | 1,603 | 1,612 | +12 | +0.8% | 5,800 |
| 2024/01/05 | 1,591 | 1,615 | 1,590 | 1,600 | +14 | +0.9% | 12,100 |
| 2024/01/04 | 1,580 | 1,590 | 1,577 | 1,586 | +25 | +1.6% | 5,300 |
| 2023/12/29 | 1,575 | 1,577 | 1,558 | 1,561 | -14 | -0.9% | 3,900 |
| 2023/12/28 | 1,566 | 1,579 | 1,557 | 1,575 | +9 | +0.6% | 3,900 |
| 2023/12/27 | 1,552 | 1,570 | 1,552 | 1,566 | +14 | +0.9% | 6,300 |
| 2023/12/26 | 1,567 | 1,569 | 1,550 | 1,552 | -12 | -0.8% | 12,600 |
| 2023/12/25 | 1,577 | 1,580 | 1,557 | 1,564 | -18 | -1.1% | 13,200 |
| 2023/12/22 | 1,600 | 1,600 | 1,577 | 1,582 | -18 | -1.1% | 17,100 |
| 2023/12/21 | 1,606 | 1,607 | 1,600 | 1,600 | -6 | -0.4% | 4,600 |
| 2023/12/20 | 1,611 | 1,613 | 1,606 | 1,606 | -6 | -0.4% | 3,800 |
| 2023/12/19 | 1,616 | 1,616 | 1,612 | 1,612 | -2 | -0.1% | 1,300 |
| 2023/12/18 | 1,618 | 1,618 | 1,611 | 1,614 | -3 | -0.2% | 1,000 |
| 2023/12/15 | 1,619 | 1,620 | 1,613 | 1,617 | -2 | -0.1% | 5,000 |
| 2023/12/14 | 1,619 | 1,623 | 1,615 | 1,619 | +1 | +0.1% | 2,200 |
| 2023/12/13 | 1,620 | 1,622 | 1,618 | 1,618 | -2 | -0.1% | 3,100 |
| 2023/12/12 | 1,623 | 1,624 | 1,619 | 1,620 | -1 | -0.1% | 4,600 |
| 2023/12/11 | 1,634 | 1,634 | 1,619 | 1,621 | -12 | -0.7% | 5,100 |
| 2023/12/08 | 1,656 | 1,656 | 1,628 | 1,633 | +8 | +0.5% | 7,400 |
| 2023/12/07 | 1,640 | 1,640 | 1,620 | 1,625 | -9 | -0.6% | 3,900 |
| 2023/12/06 | 1,613 | 1,649 | 1,613 | 1,634 | +18 | +1.1% | 17,200 |
| 2023/12/05 | 1,616 | 1,625 | 1,616 | 1,616 | -1 | -0.1% | 2,200 |
| 2023/12/04 | 1,620 | 1,628 | 1,616 | 1,617 | -7 | -0.4% | 5,200 |
| 2023/12/01 | 1,622 | 1,632 | 1,621 | 1,624 | +2 | +0.1% | 1,100 |
| 2023/11/30 | 1,626 | 1,635 | 1,622 | 1,622 | -8 | -0.5% | 3,900 |
| 2023/11/29 | 1,642 | 1,642 | 1,630 | 1,630 | -2 | -0.1% | 3,300 |
| 2023/11/28 | 1,633 | 1,644 | 1,629 | 1,632 | -6 | -0.4% | 3,400 |
| 2023/11/27 | 1,656 | 1,656 | 1,638 | 1,638 | -2 | -0.1% | 5,700 |
| 2023/11/24 | 1,649 | 1,651 | 1,631 | 1,640 | +1 | +0.1% | 6,500 |
| 2023/11/22 | 1,636 | 1,651 | 1,636 | 1,639 | +13 | +0.8% | 3,900 |
| 2023/11/21 | 1,634 | 1,644 | 1,626 | 1,626 | +9 | +0.6% | 2,200 |
| 2023/11/20 | 1,634 | 1,638 | 1,617 | 1,617 | ±0 | ±0% | 5,200 |
| 2023/11/17 | 1,620 | 1,625 | 1,617 | 1,617 | -3 | -0.2% | 2,900 |
| 2023/11/16 | 1,626 | 1,628 | 1,620 | 1,620 | ±0 | ±0% | 2,800 |
201～
250
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「日ケミファ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
| ティムス | 20,500円 | - | - | 0.00% | - | 2.78倍 |
|
東京農工大発創薬ベンチャー。黒カビ由来の急性期脳梗塞薬候補品を香港拠点ジーシンに導出 |
| ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたＣＡＲ－Ｔ細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
| カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| ＶＩＳ | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
市場注目の銘柄
チャート関連のコラム
